|Bid||0.00 x 1000|
|Ask||0.00 x 900|
|Day's range||245.03 - 261.13|
|52-week range||75.35 - 464.00|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Earnings date||09 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||332.87|
The FDA's Vaccines and Related Biological Products advisory committee recommends emergency use authorization for booster doses of J&J and Moderna's COVID-19 vaccines for use in certain adults.
In this Motley Fool Live video, recorded on Oct. 6, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not the U.S. could soon follow in Europe's footsteps. The European Medicines Agency on Monday of this week recommended the Pfizer-BioNTech booster shot for individuals ages 18 and up, and the U.S. hasn't gone that far yet with this booster authorizations.
Authorization for Moderna's (MRNA) COVID-19 vaccine for ages 12-17 was put on hold Friday in light of concerns over a rare side effect known as myocarditis, or a heart inflammation.